Introduction: Menopause Is Not a Disease — But It Is Not "Just Aging" Either
Menopause is defined retrospectively after 12 months of amenorrhea. Average onset: age 51. Perimenopause can begin 5-10 years earlier, characterized by fluctuating estrogen and progesterone levels.
The SWAN Study (Study of Women's Health Across the Nation) found that 80% of women experience vasomotor symptoms (hot flashes, night sweats), 60% have sleep disturbances, 40% report cognitive changes, and 30% develop anxiety or depression. Mean duration of vasomotor symptoms: 7.4 years. In 10% of women, symptoms persist beyond 12 years.
The Physiology of Menopause
Depletion of the ovarian follicular reserve leads to progressive decline in estradiol (the primary reproductive estrogen), progesterone, and inhibin B. FSH and LH rise compensatorily. Estradiol drops from 100-400 pg/mL to 10-20 pg/mL, affecting over 400 bodily functions: thermoregulation, bone metabolism, lipid metabolism, and neurotransmission.
The WHI Study: Groundbreaking — and Widely Misinterpreted
The Women's Health Initiative (WHI, 2002) remains the most cited study in menopausal hormone therapy. Key findings: conjugated equine estrogens (CEE, Premarin) plus medroxyprogesterone acetate (MPA, Provera) increased breast cancer risk by 26%, stroke by 41%, and thromboembolism by 113%.
However, subsequent reanalyses revealed critical nuances (Manson et al., NEJM, 2013; Hodis et al., NEJM, 2016):
- Average participant age was 63 (10+ years post-menopause) - Synthetic animal-derived hormones were used, not bioidentical compounds - Women aged 50-59 who initiated MHT within 10 years of menopause showed 30% lower all-cause mortality and 44% fewer coronary events - Estrogen-only therapy (without MPA) in hysterectomized women reduced breast cancer risk by 23%
Bioidentical vs Synthetic Hormones: Key Differences
| Class | Bioidentical | Synthetic |
|---|---|---|
| Estrogen | 17β-estradiol | CEE (Premarin) |
| Progestogen | micronized progesterone | MPA (Provera) |
| Breast cancer (E3N) | RR 1.00 | RR 1.69 |
| VTE transdermal | no increase | oral raises |
Bioidentical hormones are molecules chemically identical to endogenous human hormones:
- 17beta-estradiol — identical to ovarian estradiol. Available as transdermal patches, gels, and pellets - Micronized progesterone (Prometrium/Utrogestan) — identical to endogenous progesterone. Available as oral or vaginal capsules - Estriol — a weak estrogen used topically for urogenital atrophy
Clinical Evidence for Bioidentical Hormones
The KEEPS trial (Kronos Early Estrogen Prevention Study, 2012): transdermal estradiol in women aged 42-58 showed no increase in atherosclerosis markers while significantly improving vasomotor symptoms.
The E3N French cohort study (Fournier et al., Breast Cancer Research and Treatment, 2008): transdermal estradiol combined with micronized progesterone showed NO increased breast cancer risk (RR 1.00), while synthetic progestins raised risk (RR 1.69).
A meta-analysis in Climacteric (2019): transdermal estradiol, unlike oral estrogen, does not increase venous thromboembolism risk.
Bioidentical Therapy Formulations
Transdermal Patches and Gels
Estradiol patches (0.025-0.1 mg/day) or gels bypass hepatic first-pass metabolism, avoiding increases in clotting factors and triglycerides.
Subcutaneous Estradiol Pellets
Implanted every 3-5 months for stable estradiol levels without daily procedures. Particularly effective for severe vasomotor symptoms unresponsive to other delivery methods.
Micronized Progesterone
100-200 mg at bedtime. Provides anxiolytic and sedative effects through its metabolite allopregnanolone (a GABA receptor agonist). Protects the endometrium from hyperplasia during estrogen therapy.
Custom Compounded Formulations
Compounding pharmacies prepare personalized formulas (creams, gels, capsules) with precise hormone ratios. Advantage: individualized dosing. Limitation: lack of standardized quality control.
Bone and Cardiovascular Protection
Bone loss accelerates during the first 5-7 years post-menopause — up to 3-5% annually. Estrogen therapy is the only intervention that can not only slow but reverse early osteoporosis (Cauley et al., JAMA, 2003: 34% reduction in hip fractures).
Cardioprotection: the DOPS trial (Danish Osteoporosis Prevention Study, Schierbeck et al., BMJ, 2012) — 10 years of MHT initiated in early menopause reduced heart failure and myocardial infarction risk by 52% with no increase in cancer risk.
Frequently Asked Questions
Is hormone therapy safe after age 60? Initiating MHT more than 10 years after menopause or after age 60 is not recommended due to elevated cardiovascular risk. However, women already on MHT may continue under supervision.
Do bioidentical hormones increase cancer risk? Transdermal estradiol plus micronized progesterone is the safest combination. The French E3N cohort found no increased breast cancer risk.
How long can MHT be taken? Current guidelines (IMS, 2023): the decision is individualized with no arbitrary duration limit. Annual reassessment of risk-benefit ratio is recommended.
How do compounded hormones differ from pharmaceutical-grade? The molecules are identical. The difference lies in delivery form and dosing precision. FDA-approved products undergo standardized quality control; compounded formulations do not.
Is progesterone needed after hysterectomy? For endometrial protection, no. But micronized progesterone has independent neuroprotective and anxiolytic effects, so many experts recommend it even post-hysterectomy.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
🌀
Laboratory Monitoring Protocol on Bioidentical Hormone Therapy
The article cites transdermal estradiol dosing in micrograms but provides no laboratory targets to confirm physiological replacement. Without monitoring, "bioidentical" remains a marketing label rather than a measurable clinical state. The following biochemical framework is consistent with North American Menopause Society and Endocrine Society positions.
Salivary and capillary "hormone panels" marketed by compounding pharmacies show poor correlation with serum levels and high intra-assay variability; they should not guide dosing. When a patient arrives with prior salivary results, repeat serum testing before any titration decision.
🌀
Absolute and Relative Contraindications
The article advocates therapy initiation in early postmenopause but does not define who should not be treated. Patient selection determines the benefit-risk ratio more than formulation choice.
Relative contraindications requiring individualized risk discussion. Migraine with aura — transdermal route only, because oral estrogen increases ischemic stroke risk in this population. Uncontrolled hypertension above 160/100 mmHg should be normalized before initiation. Symptomatic gallbladder disease — oral estrogen increases cholelithiasis risk approximately 1.5-fold; transdermal does not. [PMID: 28785204[1]] Hypertriglyceridemia above 4.5 mmol/L (400 mg/dL) — oral estrogen raises triglycerides 24–38% via first-pass hepatic effect and can precipitate pancreatitis; transdermal lowers or does not change triglycerides. Family history of breast cancer is not a contraindication; BRCA1/2 carriers without prior cancer may receive short-term therapy after risk-reduction surgery with shared decision-making. [PMID: 29581723[3]]
Conditions requiring specialist clearance before initiation. Endometriosis history may flare on estrogen monotherapy and mandates continuous combined regimen. Uterine fibroids larger than 5 cm may grow; baseline pelvic ultrasound establishes a reference for surveillance. Otosclerosis can progress on systemic estrogen and warrants ENT consultation. Systemic lupus erythematosus without antiphospholipid antibodies is not a contraindication; with antiphospholipid antibodies, therapy is contraindicated. Patients on aromatase inhibitors for breast cancer prevention should not receive systemic estrogen.
🌀
Genitourinary Syndrome of Menopause: Local Estriol Protocol
Genitourinary syndrome of menopause (GSM) affects approximately 50% of postmenopausal women and includes vaginal dryness, dyspareunia, urinary urgency, and recurrent urinary tract infection. Systemic therapy resolves GSM in only 40–75% of cases; the remainder require local treatment. The article mentions estriol once — concrete dosing follows.
🌀
Discontinuation and Reassessment
No menopausal therapy is intended to be permanent without periodic reassessment. The article omits exit strategy, which is as clinically important as initiation.
References
Key facts
- Average menopause onset is age 51; vasomotor symptoms last a mean of 7.4 years (SWAN).
- 80% of women have vasomotor symptoms, 60% sleep disturbance, 30% anxiety or depression.
- Estradiol drops from 100–400 to 10–20 pg/mL, affecting over 400 bodily functions.
- Transdermal estradiol + micronized progesterone: breast cancer RR 1.00 (E3N cohort).
- Bone loss reaches 3–5% per year in the first 5–7 years post-menopause.
